MedPath

A phase 2 study of transcatheter aterial chemoembolization using cisplatin and DC beads for advanced hepatocellular carcinoma

Phase 2
Recruiting
Conditions
HCC
Registration Number
JPRN-UMIN000028000
Lead Sponsor
ational Hospital Organization KURE Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

(1)HCC without stain on angiogram. (2)History of hypersensitivity to cisplatinum-containing drug. (3)distant metastasis (4)main portal tumor thrombosis or hepatic vein tumor thrombosis (5)Patients with intrahepatic AP shunt or AV shunt. (6)Patients with complications to be treated preferentially. (7)Patients who can not keep their rest during the procedure. (8)Patients who are concluded to be inappropriate to participate in this study by their physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate(RR) 3 months after TACE
Secondary Outcome Measures
NameTimeMethod
Safty Tumor markers
© Copyright 2025. All Rights Reserved by MedPath